KUVATRIS THERAPEUTICS, INC. Operating Expenses
KUVATRIS THERAPEUTICS, INC. reported Operating Expenses of $887.94 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2026-01-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-01-14
- KUVATRIS THERAPEUTICS, INC. operating expenses for the quarter ending 2024-09-30 was $887.94K, a 79.66% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. operating expenses for the quarter ending 2024-06-30 was $3.00M, a 10.70% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. operating expenses for the quarter ending 2024-03-31 was $3.69M, a 8.58% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. operating expenses for the quarter ending 2023-12-31 was $4.43M, a 10.90% decline year-over-year.
- KUVATRIS THERAPEUTICS, INC. operating expenses for fiscal 2023 was $16.15M, a 52.25% increase from fiscal 2022.
- KUVATRIS THERAPEUTICS, INC. operating expenses for fiscal 2022 was $10.60M, a 47.33% increase from fiscal 2021.
- KUVATRIS THERAPEUTICS, INC. operating expenses for fiscal 2021 was $7.20M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $887.94K 10-Q · filed 2026-01-14 | $3.89M derived: sum of 2 quarters · filed 2026-01-14 | $7.58M 10-Q · filed 2026-01-14 | $12.01M derived: sum of 4 quarters · filed 2026-01-14 | |
| 2024-06-30 | $3.00M 10-Q · filed 2024-09-20 | $6.69M 10-Q · filed 2024-09-20 | $11.12M derived: sum of 3 quarters · filed 2024-09-20 | $15.49M derived: sum of 4 quarters · filed 2026-01-14 | |
| 2024-03-31 | $3.69M 10-Q · filed 2024-05-13 | $8.12M derived: sum of 2 quarters · filed 2024-05-13 | $12.49M derived: sum of 3 quarters · filed 2026-01-14 | $15.85M derived: sum of 4 quarters · filed 2026-01-14 | |
| 2023-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $8.80M derived: sum of 2 quarters · filed 2026-01-14 | $12.16M derived: sum of 3 quarters · filed 2026-01-14 | $16.15M 10-K · filed 2024-03-11 | |
| 2023-09-30 | $4.36M 10-Q · filed 2026-01-14 | $7.72M derived: sum of 2 quarters · filed 2026-01-14 | $11.71M 10-Q · filed 2026-01-14 | $11.76M 10-Q · filed 2023-11-16 | $16.74M derived: sum of 4 quarters · filed 2026-01-14 |
| 2023-06-30 | $3.36M 10-Q · filed 2024-09-20 | $7.39M 10-Q · filed 2024-09-20 | $12.37M derived: sum of 3 quarters · filed 2024-09-20 | $15.07M derived: sum of 4 quarters · filed 2024-09-20 | |
| 2023-03-31 | $4.04M 10-Q · filed 2024-05-13 | $9.01M derived: sum of 2 quarters · filed 2024-05-13 | $11.71M derived: sum of 3 quarters · filed 2024-05-13 | $12.64M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $7.67M derived: sum of 2 quarters · filed 2024-03-11 | $8.60M derived: sum of 3 quarters · filed 2024-03-11 | $10.60M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $2.69M 10-Q · filed 2023-11-16 | $3.62M derived: sum of 2 quarters · filed 2023-11-16 | $5.63M 10-Q · filed 2023-11-16 | $7.42M derived: sum of 4 quarters · filed 2023-11-16 | |
| 2022-06-30 | $927.39K 10-Q · filed 2023-08-09 | $2.93M 10-Q · filed 2023-08-09 | $4.72M derived: sum of 3 quarters · filed 2023-08-09 | $6.44M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-15 | $3.80M derived: sum of 2 quarters · filed 2023-05-15 | $5.51M derived: sum of 3 quarters · filed 2023-05-15 | $7.49M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.51M derived: sum of 2 quarters · filed 2023-03-30 | $5.48M derived: sum of 3 quarters · filed 2023-03-30 | $7.20M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.71M 10-Q · filed 2022-11-14 | $3.69M derived: sum of 2 quarters · filed 2022-11-14 | $5.41M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $1.98M 10-Q · filed 2022-09-30 | $3.69M 10-Q · filed 2022-09-30 |